Search results for "anticonvulsant"

showing 10 items of 141 documents

No evidence for efficacy of intrathecal verapamil in the treatment of tonic-clonic status epilepticus

1992

In two patients with refractory generalized tonic-clonic status epilepticus, 15 mg of the calcium antagonist verapamil was given by suboccipital intrathecal administration. During a 2–6-h observation period, seizure frequency did not decrease. However, in one patient, verapamil induced severe hypotension. Subsequent thiopental anesthesia suppressed convulsions immediately. Our results indicate that, in contradistinction to animal studies with different administration techniques, intrathecal administration of verapamil does not produce any anticonvulsant effect in humans.

business.industryGeneral Neurosciencemedicine.medical_treatmentAntagonistchemistry.chemical_elementStatus epilepticusPharmacologyCalciumIntrathecalTonic (physiology)AnticonvulsantchemistryAnesthesiamedicineVerapamilNeurology (clinical)Animal studiesmedicine.symptombusinessmedicine.drugJournal of Epilepsy
researchProduct

Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments.

2018

Abstract Despite significant advances in pharmacological and non-pharmacological treatments, mood disorders remain a significant source of mental capital loss, with high rates of treatment resistance, requiring a coordinated effort in investigation and development of efficient, tolerable and accessible novel interventions. Ketogenic diet (KD) is a low-carb diet that substantially changes the energetic matrix of the body including the brain. It has been established as an effective anticonvulsant treatment, and more recently, the role of KD for mental disorders has been explored. Ketogenic diet has profound effects in multiple targets implicated in the pathophysiology of mood disorders, inclu…

business.industryMood DisordersCognitive Neurosciencemedicine.medical_treatmentPsychological interventionBioinformaticsmedicine.disease030227 psychiatry03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineNeuropsychology and Physiological PsychologyAnticonvulsantMoodMood disordersmedicineAntidepressantAnimalsHumansBipolar disorderMetabolic syndromebusinessDiet Ketogenic030217 neurology & neurosurgeryKetogenic dietNeuroscience and biobehavioral reviews
researchProduct

Cannabis Influences the Putative Cytokines-Related Pathway of Epilepsy among Egyptian Epileptic Patients

2019

The study aims to investigate: (1) the prevalence of cannabis among epileptic patients seen at Mansoura University Hospital, (2) serum levels and gene expression of cytokines in epilepsy patients and the controls. and (3) the possibility that cannabis use affects the cytokine levels in epilepsy patients, triggering its future use in treatment. We recruited 440 epilepsy patients and 200 controls matched for age, gender, and ethnicity. Of the epileptic patients, 37.5% demonstrated lifetime cannabis use with a mean duration of 15 &plusmn

cannabismedicine.medical_specialtypurified cannabidiol (cbd)inflammatory cytokinesmedicine.medical_treatmenttreatment-resistant epilepsyArticlelcsh:RC321-571Proinflammatory cytokine03 medical and health sciencesEpilepsy0302 clinical medicineInternal medicinemedicineanticonvulsant drugslcsh:Neurosciences. Biological psychiatry. Neuropsychiatryseizures030304 developmental biology0303 health sciencesbiologybusiness.industryGeneral NeuroscienceInterleukintetrahydrocannabinol (thc)Cannabis useUniversity hospitalbiology.organism_classificationmedicine.diseaseCytokineepilepsyTumor necrosis factor alphaCannabisbusiness030217 neurology & neurosurgeryBrain Sciences
researchProduct

Recurrence rates in bipolar disorder: Systematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials

2015

Bipolar disorder (BD) is a recurrent, lifelong illness with high risks of disability and excess mortality. Despite many treatment options with demonstrated short-term efficacy, evidence concerning long-term treatment effectiveness in BD remains limited and the relative value of naturalistic studies versus randomized, controlled trials (RCTs) in its assessment, uncertain. Systematic computer-searching yielded 10 naturalistic studies and 15 RCTs suitable for analysis of recurrence rates and their association with treatments and selected clinical factors. In naturalistic studies (3904 BD subjects, 53.3% women, 85.8% BD-I, mean onset age 29.1, followed up to 2.1 years), the pooled recurrence ra…

medicine.medical_specialtyBipolar DisorderCIENCIAS MÉDICAS Y DE LA SALUDmedicine.medical_treatmentCiencias de la SaludPlaceboRELAPSElaw.inventionRandomized controlled trialRecurrencelawInternal medicinemedicineHumansPharmacology (medical)Bipolar disorderPsychiatryBiological PsychiatryDepression (differential diagnoses)Randomized Controlled Trials as TopicPharmacologyExcess mortalitySalud OcupacionalNATURALISTICTreatment optionsBIPOLAR DISORDERmedicine.diseaseDEPRESSIONPsychiatry and Mental healthTreatment OutcomeAnticonvulsantNeurologyNeurology (clinical)Psychology
researchProduct

Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysi…

2010

In recent years, combinations of pharmacological treatments have become common for the treatment of bipolar disorder type I (BP I); however, this practice is usually not evidence-based and rarely considers monotherapy drug regimen (MDR) as an option in the treatment of acute phases of BP I. Therefore, we evaluated comparative data of commonly prescribed MDRs for both manic and depressive phases of BP I. Medline, PsycINFO, EMBASE, the Cochrane Library, the ClinicalStudyResults.org and other data sources were searched from 1949 to March 2009 for placebo and active controlled randomized clinical trials (RCTs). Risk ratios (RRs) for response, remission, and discontinuation rates due to adverse …

medicine.medical_specialtyBipolar I disorderBipolar DisorderDatabases FactualPharmacologyLithiumArticlelaw.inventionTreatment of bipolar disorderRandomized controlled triallawInternal medicinemental disordersmedicineAnimalsHumansManic-depressive illnessPharmacology (medical)Bipolar disorderAntipsychotic drugsRandomized Controlled Trials as TopicPharmacologyTrastorn bipolarbusiness.industrymedicine.diseaseLitiAntidepressive AgentsDiscontinuationPsychiatry and Mental healthAcute DiseaseNumber needed to treatAnticonvulsiusQuetiapineDrug EvaluationAntipsicòticsAnticonvulsantsmedicine.symptombusinessManiamedicine.drug
researchProduct

Neurocognition in bipolar disorders—A closer look at comorbidities and medications

2010

The last decade has witnessed a growing interest in the neuropsychological study of bipolar disorder (BD). This chronic mood disorder is associated with persistent neurocognitive impairments even during periods of euthymia, particularly in the broad domains of attention, verbal memory and executive functions. More interestingly, cognitive dysfunction seems to predict a poorer functional outcome among BD patients and thus represents an important target for future therapies. The aetiology of cognitive dysfunction is probably multifactorial, including gene-environment interactions with potentially confounding variables as well. Drug-induced cognitive adverse effects represent an important and …

medicine.medical_specialtyBipolar disorderComorbidityLithiumAntipsychoticNeuropsychologyAnticonvulsantmedicineAnimalsHumansBipolar disorderPsychiatryPharmacologyNeuropsychologyCognitionIatrogenic effectmedicine.diseaseExecutive functionsComorbidityPharmaceutical PreparationsObservational studyVerbal memoryCognition DisordersPsychologyNeurocognitiveClinical psychologyEuropean Journal of Pharmacology
researchProduct

Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review.

2020

Background and Objectives: Distal symmetrical polyneuropathy (DSPN) is one of the most common chronic complications of diabetes mellitus. Although it is usually characterized by progressive sensory loss, some patients may develop chronic pain. Assessment of DSPN is not difficult, but the biggest challenge is making the correct diagnosis and choosing the right treatment. The treatment of DSPN has three primary objectives: glycemic control, pathogenic mechanisms, and pain management. The aim of this brief narrative review is to summarize the current pharmacological treatment of painful DSPN. It also summarizes knowledge on pathogenesis-oriented therapy, which is generally overlooked in many p…

medicine.medical_specialtyDiabetic neuropathyAdministration TopicalMEDLINEPregabalinReviewCochrane LibraryDiabetic Neuropathiespharmacological treatmentDiabetes mellitusMedicineHumansPain ManagementpainIntensive care medicinelcsh:R5-920business.industryDiabetes mellitus Neuropathy Pain Pharmacological treatment Administration Topical Analgesics Opioid Anticonvulsants Antidepressive Agents Diabetic Neuropathies Humans Pain ManagementChronic painGeneral Medicinemedicine.diseaseAntidepressive AgentsAnalgesics OpioidNeuropathic paindiabetes mellitusAnticonvulsantsneuropathylcsh:Medicine (General)businessPolyneuropathymedicine.drugMedicina (Kaunas, Lithuania)
researchProduct

Antiepileptic drugs for the treatment of neuropathic pain : a systematic review

2012

Many therapies have been proposed for the management of neuropathic pain, and they include the use of different antiepileptic drugs. However, the lack of high quality studies indicates that results on the different neuropathic disorders under study do not recommend a particular drug treatment. This study makes a systematic review of the published literature on the use of several antiepileptic drugs to treat neuropathic pain, and has the objective of considering both its clinical characteristics and pharmacological use, which will depend on their level of scientific evidence and will follow the principles of evidence-based dentistry. The articles were stratified according to their scientific…

medicine.medical_specialtyNeuràlgia del trigeminAlternative medicineMEDLINERessenyes sistemàtiques (Investigació mèdica)Scientific evidencelaw.inventionMalalties del sistema nerviósDrug treatmentRandomized controlled trialSystematic reviews (Medical research)lawmedicineHumansIntensive care medicinePsychiatryGeneral Dentistrybusiness.industryReview-ArticleNervous system Diseases:CIENCIAS MÉDICAS [UNESCO]Jadad scaleOrofacial Pain - TMJDClinical trialOtorhinolaryngologyNeuropathic painUNESCO::CIENCIAS MÉDICASAnticonvulsiusNeuralgiaAnticonvulsantsSurgerybusinessTrigeminal neuralgia
researchProduct

Nonketotic hyperglycinemia and epilepsy

2015

Nonketotic hyperglycinemia (NKH) is an autosomal recessive inborn error in the glycine degradation pathway resulting in severe neurological impairment with intractable seizures and brain damage in the majority of the affected patients. Depending on the age of onset and on the outcome of the disease, severe and attenuated forms of NKH may be discriminated. During neonatal period, patients may present with early myoclonic encephalopathy; in the course of the disease, the picture of seizures changes, and multiple forms of seizures may occur. In patients with severe NKH, seizures remain persistent and resistant to anticonvulsant treatment. Variant NKH, caused by mutations resulting in a deficie…

medicine.medical_specialtyPediatricsHyperglycinemiabusiness.industrymedicine.medical_treatmentBrain damagemedicine.diseaseGlycine encephalopathyEpilepsyEndocrinologyAnticonvulsantNeurotransmitter receptorInternal medicinePediatrics Perinatology and Child HealthmedicineNeurology (clinical)medicine.symptomAge of onsetbusinessEarly myoclonic encephalopathyJournal of Pediatric Epilepsy
researchProduct

Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double-blind, placebo-controlled st…

2000

INTRODUCTION A multicentre, randomized, double-blind, placebo-controlled, parallel group study was carried out in 123 patients suffering from never treated (de novo) idiopathic Parkinson's disease (PD). The aim of the study was to confirm the efficiency and safety of alpha-dihydroergocryptine (alpha-DHEC) given as monotherapy in the symptomatic treatment of PD. The total score of the Unified Parkinson's Disease Rating Scale (UPDRS) was identified as the efficacy target variable. PATIENTS AND METHODS Sixty-two patients (32 males, 30 females, mean age +/- SD 64 +/- 10) were randomized to alpha-dihydroergocryptine and 61 (30 males, 31 females, mean age 63.8 +/- 9.1) to placebo. According to th…

medicine.medical_specialtybusiness.industryIncidence (epidemiology)medicine.medical_treatmentPlacebo-controlled studyGeneral MedicineInterim analysisPlacebomedicine.diseaseSurgeryCentral nervous system diseaseAnticonvulsantNeurologyInternal medicineStatistical significancemedicineNeurology (clinical)Analysis of variancebusinessActa Neurologica Scandinavica
researchProduct